Abstract
Purpose To describe the correlation between facial palsy of any etiology and Meibomian gland dysfunction and to report the tear film parameters found in patients with facial palsy diagnosis.
Design Observational, longitudinal, and comparative study.
Methods A sample of 20 patients with unilateral facial palsy was obtained its severity was staged using the House-Brackmann scale. A dry eye evaluation using an Oculus 5M keratograph was performed, which included infrared meibography, tear breakup time, and a dry eye questionnaire. Meibographies were analyzed using ImageJ software to determine the affected area.
Results 11 patients (55%) were female, mean age of diagnosis was 57.80 ± 18.28 (range of 22-80), 10 (50%) cases were due to Bell’s palsy. Tear breakup time was markedly reduced in the affected side but was statistically insignificant (p=0.2167) and tear meniscus height was much greater in the non-affected side (p=0.0199). Finally, Meibomian gland alterations were more evident in the affected side, with upper Meibomian glands having a loss of 29.55 ± 13.31 percent (p=0.0374) and lower glands presenting a loss 44.44 ± 16.9 percent (p=<0.001).
Conclusions A clear difference in Meibomian gland and tear film dynamics can be observed in paretic vs non paretic sides in the same patients. Multiple mechanisms contribute to this ailment, such as an incomplete blinking pattern and Meibomian gland dysfunction due to orbicularis oculi weakness. Software based analysis also showed a greater glandular area loss when compared to clinician’s analysis, which may help aide in therapeutic decisions for patients with meibomian gland dysfunction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local ethics committee (Comite de Etica Tecnologico de Monterrey) in February 2020 according to the Helsinki declaration under the registration number: P000302-CDLPPFU. Informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
